4. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014 Sep 4;6(10):a016295. doi: 10.1101/cshperspect.a016295. PMID: 25190079; PMCID: PMC4176007. 5
参考文献: [1] Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and diseas[J]. Cold Spring Harb Perspect Biol. 2014 Sep 4;6(10):a016295. [2] Uciechowski P, Dempke WCM. Interleukin-6: A Masterplayer in the Cytokine Network[J]. Oncology. 2020;98(3):131-137....
[6].The role of IL‑6 in host defence against infections: immunobiology and clinical implications. [7].IL-6 in Inflammation, Immunity, and Disease. [8].Immunotherapeutic implications of IL-6 blockade for cytokine storm. [9].IL-6 as a keystone cytokine in health and disease. [10].Target...
[6].The role of IL‑6 in host defence against infections: immunobiology and clinical implications. [7].IL-6 in Inflammation, Immunity, and Disease. [8].Immunotherapeutic implications of IL-6 blockade for cytokine storm. [9].IL-6 as a keystone cytokine in health and disease. [10].Target...
[6].The role of IL‑6 in host defence against infections: immunobiology and clinical implications. [7].IL-6 in Inflammation, Immunity, and Disease. [8].Immunotherapeutic implications of IL-6 blockade for cytokine storm. [9].IL-6 as a keystone cytokine in health and disease. ...
[7].IL-6 in Inflammation, Immunity, and Disease. [8].Immunotherapeutic implications of IL-6 blockade for cytokine storm. [9].IL-6 as a keystone cytokine in health and disease. [10].Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. ...
IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6:a016295. Article PubMed PubMed Central Google Scholar Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011;121:3375–83. ...
Sanda, SrinathJohn Wiley & Sons, Ltd.Immunity Inflammation & DiseaseSpindler MP, Ho AM, Tridgell D, McCulloch-Olson M, Gersuk V, Ni C, et al. Acute hyperglycemia impairs IL-6 expression in humans. Immun Inflamm Dis. 2016;4:91-7....
Inhibiting the inflammasome-induced activation of pro-inflammatory cytokines has shown beneficial effects in human disease models and multiple pharmacological inhibitors of the NLRP3 inflammasome have been identified [11], [12]. Currently anakinra (IL-1 receptor agonist), canakinumab (neutralizing anti ...
[1]. Frorath B, et al. Production of recombinant rat interleukin-6 in Escherichia coli using a novel highly efficient expression vector pGEX-3T. Send to [2]. Tanaka T, et al. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014 Sep 4;6(10):a016295....